Epstein-Barr virus latent membrane protein 1 peptide–HLA class I complex (EBV LMP1-HLA-I complex)

The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) peptide–HLA class I complex is a specific molecular target consisting of an 8- to 11-amino acid fragment of the LMP1 protein bound within the groove of a Human Leukocyte Antigen (HLA) class I molecule. LMP1 is a primary oncogene of EBV, essential for B-cell transformation and frequently expressed in EBV-associated malignancies such as nasopharyngeal carcinoma and Hodgkin lymphoma (Source: PubMed, PMID: 30243505). Because LMP1 is an intracellular protein, it is not accessible to traditional monoclonal antibodies; however, its degradation products are presented on the cell surface by HLA molecules, making the pMHC complex a viable target for T-cell receptor (TCR)-based therapies and TCR-like antibodies (Source: Nature Communications, PMID: 32665556). Therapeutic strategies targeting these complexes aim to harness the precision of the cellular immune system to eliminate EBV-positive tumor cells while sparing healthy tissue. Clinical development focuses on adoptive T-cell therapies, including TCR-engineered T cells (TCR-T) and EBV-specific cytotoxic T lymphocytes (CTLs), which recognize specific LMP1 epitopes like YLQQNWWTL in the context of HLA-A*02:01 (Source: Blood, PMID: 24925916). Challenges in targeting this complex include the high polymorphism of HLA alleles across different populations and the potential for immune evasion through the loss of HLA expression by tumor cells.

Other names

LMP1-HLA complexEBV LMP1-MHC class I complexLMP1-derived peptide-HLA-A*02:01 complexEBV LMP1-HLA-A2 complexpMHC complex (LMP1)

Targeted by T-cell receptors (TCRs) or TCR-mimetic antibodies to induce cytotoxic T-lymphocyte (CTL) mediated lysis of EBV-infected or transformed cells presenting the LMP1 peptide.